GENENTA SCIENCE(SP.ADR)/1 (K5F) - Total Liabilities
Based on the latest financial reports, GENENTA SCIENCE(SP.ADR)/1 (K5F) has total liabilities worth €10.05 Million EUR (≈ $11.75 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check GENENTA SCIENCE(SP.ADR)/1 (K5F) liquid assets ratio to evaluate the company's liquid asset resilience ratio.
GENENTA SCIENCE(SP.ADR)/1 - Total Liabilities Trend (2021–2025)
This chart illustrates how GENENTA SCIENCE(SP.ADR)/1's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see K5F total asset value.
GENENTA SCIENCE(SP.ADR)/1 Competitors by Total Liabilities
The table below lists competitors of GENENTA SCIENCE(SP.ADR)/1 ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Spirent Communications plc
LSE:SPT
|
UK | GBX199.60 Million |
|
Cyclacel Pharmaceuticals Inc
NASDAQ:CYCC
|
USA | $770.00 |
|
BBI Development S.A.
WAR:BBD
|
Poland | zł97.45 Million |
|
Bodhi Tree Multimedia Limited
NSE:BTML
|
India | Rs817.62 Million |
|
Ryukil C&S Ltd
KQ:191410
|
Korea | ₩33.07 Billion |
|
Beeio Honey Ltd
TA:WTS
|
Israel | ILA1.62 Million |
|
Lancartama Sejati Tbk
JK:TAMA
|
Indonesia | Rp144.73 Billion |
|
Magnum Ventures Limited
NSE:MAGNUM
|
India | Rs5.79 Billion |
Liability Composition Analysis (2021–2025)
This chart breaks down GENENTA SCIENCE(SP.ADR)/1's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See K5F net asset quality index to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 14.16 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.46 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.32 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how GENENTA SCIENCE(SP.ADR)/1's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for GENENTA SCIENCE(SP.ADR)/1 (2021–2025)
The table below shows the annual total liabilities of GENENTA SCIENCE(SP.ADR)/1 from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €10.05 Million ≈ $11.75 Million |
+331.59% |
| 2024-12-31 | €2.33 Million ≈ $2.72 Million |
+21.59% |
| 2023-12-31 | €1.91 Million ≈ $2.24 Million |
-16.73% |
| 2022-12-31 | €2.30 Million ≈ $2.69 Million |
+97.29% |
| 2021-12-31 | €1.17 Million ≈ $1.36 Million |
-- |
About GENENTA SCIENCE(SP.ADR)/1
Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. The company is developing Temferon for us… Read more